RxDoctor Payments Data

Michael Shen, MD

Neurology · Laguna Hills, CANPI 1154402238

Payments from drug & device makers

$100,512in general payments, 2019–2025

Across 625 payments — averaging $160.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$86K
  • AbbVie$2K
  • UCB, Inc.$2K
  • Neurocrine Biosciences, Inc.$1K
  • AstraZeneca$794
  • Eisai Inc.$623
  • plus $8K from 54 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$13,88799%
  • Education$1541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly4$86,447
AbbVie(2 entities)106$1,940
UCB, Inc.55$1,572
Neurocrine Biosciences, Inc.44$1,016
AstraZeneca(2 entities)31$794
Eisai Inc.26$623
Lilly USA, LLC30$614
Argenx US, Inc.21$577
Biogen23$555
SK Life Science, Inc.25$490
Pfizer24$465
Amgen(2 entities)17$455
Lundbeck LLC19$365
Octapharma USA, Inc.7$350
Novartis17$321
ANI Pharmaceuticals, Inc.10$290
Otsuka America Pharmaceutical, Inc.12$266
Johnson & Johnson(2 entities)7$222
EMD Serono, Inc.11$219
Livanova USA, Inc.10$195
MDD US Operations, LLC6$170
Teva Pharmaceuticals USA, Inc.9$168
Amneal Pharmaceuticals LLC9$164
Sunovion Pharmaceuticals Inc.8$154
Boston Scientific7$131
Adamas Pharmaceuticals, Inc.5$120
GE HealthCare5$114
Sanofi5$106
Takeda Pharmaceuticals U.S.A., Inc.4$100
W. L. Gore & Associates, Inc.4$100
Acadia Pharmaceuticals Inc4$97
Genentech USA, Inc.4$91
Tanabe Pharma America, Inc.4$89
Bristol Myers Squibb3$83
Scilex Pharmaceuticals Inc.5$82
Grifols USA, LLC3$72
CSL Behring4$71
Axsome Therapeutics, Inc.2$71
Alnylam Pharmaceuticals Inc.3$70
Avion Pharmaceuticals3$60
Kyowa Kirin, Inc.3$57
Supernus Pharmaceuticals, Inc.1$51
Upsher-smith Laboratories LLC2$49
Neuropace, Inc.1$45
Biohaven Pharmaceutical Holding Company Ltd.2$40
Assertio Therapeutics, Inc.2$32
Biohaven Pharmaceuticals, Inc.2$30
Abbott2$28
Ipsen Biopharmaceuticals, Inc1$28
Mallinckrodt Hospital Products Inc.1$27
Mallinckrodt Enterprises LLC1$26
Avanir Pharmaceuticals, Inc.1$24
Averitas Pharma Inc.1$24
Acorda Therapeutics, Inc1$24
Vertical Pharmaceuticals, LLC1$23
Corium, LLC1$19
Biotronik Inc.1$18
Strongbridge US Inc.1$18
Vanda Pharmaceuticals Inc.1$17
Arbor Pharmaceuticals, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,512 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$202,750
Medicare patients
241
Services billed
1,197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$113,176
RexultiBrexpiprazole22$34,924
BriviactBrivaracetam12$17,329
VimpatLacosamide13$16,736
RytaryCarbidopa/Levodopa17$14,507
Gabapentin318$7,743
Pregabalin204$6,374
Duloxetine Hcl202$5,265
Memantine Hcl134$4,724
DilantinPhenytoin Sodium Extended14$4,265
Levetiracetam ErLevetiracetam62$3,991
Carbidopa-LevodopaCarbidopa/Levodopa93$3,242
Carbidopa-Levodopa ErCarbidopa/Levodopa39$2,641
Levetiracetam89$2,421
Divalproex Sodium95$2,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$1,016$113,17615 claims
Otsuka America Pharmaceutical, Inc.Rexulti$266$34,92422 claims
UCB, Inc.Briviact, Vimpat$1,572$34,06625 claims
Amneal Pharmaceuticals LLCRytary$164$14,50717 claims
PfizerDilantin$465$4,26514 claims
Lilly USA, LLCOlanzapine$614$38222 claims
Upsher-smith Laboratories LLCTopiramate$49$15911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →